Shuldiner; Alan

Patent Applications and Registrations

Patent applications and USPTO patent grants for Shuldiner; Alan.The latest application filed is for "hsd17b13 variants and uses thereof".

Company Profile

6.7.18

Shuldiner; Alan - Tarrytown NY
Shuldiner; Alan - Baltimore MD
SHULDINER; ALAN - COLUMBIA MD

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
HSD17B13 Variants And Uses Thereof App 20220267743 - Abul-Husn; Noura S. ; et al.	2022-08-25
Rodent Model Of Increased Bone Mineral Density App 20220217956 - Tang; Yajun ; et al.	2022-07-14
Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (SCAP) inhibitors Grant 11,331,332 - Gong , et al. May 17, 2	2022-05-17
17 -Hydroxysteroid Dehydrogenase Type 13 (HSD17B13) iRNA Compositions And Methods Of Use Thereof App 20210380985 - Hinkle; Gregory ; et al.	2021-12-09
17.beta.-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof Grant 11,180,757 - Hinkle , et al. November 23, 2	2021-11-23
A Rodent Model Of B4galt1-mediated Functions App 20210274759 - Gatta; Giusy Della ; et al.	2021-09-09
Treatment Of Decreased Bone Mineral Density With Zinc And Ring Finger 3 (ZNRF3) Inhibitors App 20210002647 - Gong; Da-Wei ; et al.	2021-01-07
B4GALT1 Variants And Uses Thereof App 20200399617 - Montasser; May ; et al.	2020-12-24
Hsd17b13 Variants And Uses Thereof App 20200354693 - Abul-Husn; Noura S. ; et al.	2020-11-12
HSD17B13 variants and uses thereof Grant 10,787,647 - Abul-Husn , et al. September 29, 2	2020-09-29
Treatment Of Increased Lipid Levels With Sterol Regulatory Element Binding Transcription Factor 1 (SREBF1) Inhibitors App 20200297752 - Shuldiner; Alan ; et al.	2020-09-24
Treatment Of Increased Lipid Levels With Sterol Regulatory Element Binding Protein Cleavage-Activating Protein (SCAP) Inhibitors App 20200297753 - Gong; Da-Wei ; et al.	2020-09-24
B4GALT1 cDNA variants and compositions comprising the same Grant 10,738,284 - Montasser , et al. A	2020-08-11
Methods for treating cardiovascular dysfunction and improving fluid homeostasis with Elabela peptide hormone Grant 10,463,716 - Gong , et al. No	2019-11-05
B4GALT1 Variants And Uses Thereof App 20180346888 - Montasser; May ; et al.	2018-12-06
HSD17B13 Variants And Uses Thereof App 20180216104 - Abul-Husn; Noura S. ; et al.	2018-08-02
Hsd17b13 Variants And Uses Thereof App 20180216084 - Abul-Husn; Noura S. ; et al.	2018-08-02
Methods For Treating Cardiovascular Dysfunction And Improving Fluid Homeostasis With A Peptide Hormone App 20170224779 - Gong; Da-Wei ; et al.	2017-08-10
Method Of Modifying Glucose Activity Using Polypeptides Selectively Expressed In Fat Tissue App 20090317393 - GONG; DA-WEI ; et al.	2009-12-24
Method of modifying glucose activity using polypeptides selectively expressed in fat tissue Grant 7,550,435 - Gong , et al. June 23, 2	2009-06-23
Method Of Modifying Glucose Activity Using Polypeptides Selectively Expressed In Fat Tissue App 20080085864 - Gong; Da-Wei ; et al.	2008-04-10
Method of modifying glucose activity using polypeptides selectively expressed in fat tissue Grant 7,312,197 - Gong , et al. December 25, 2	2007-12-25
Novel alanine transaminase enzyme and methods of use App 20050214883 - Gong, Da-Wei ; et al.	2005-09-29
Novel alanine transaminase enzyme and methods of use App 20040234977 - Gong, Da-Wei ; et al.	2004-11-25
Polypeptides selectively expressed in fat tissue and methods for use thereof App 20040220099 - Gong, Da-Wei ; et al.	2004-11-04

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.